May 7, 2009 |
The federal government has given the green light for Sanofi Pasteur Inc. to manufacture flu vaccine at its Poconos site, a boost to the country's ability to cope with future flu outbreaks. The U.S. Food and Drug Administration said it approved the facility, in Swiftwater, Pa., to produce seasonal influenza vaccine. The agency also said the facility could make a vaccine against the new 2009 H1N1 influenza strain. The Centers for Disease Control and Prevention has not yet decided whether to create a vaccine against that strain.
July 28, 2008 |
PARIS - Sanofi-Aventis SA said its planned $551 million acquisition of Acambis PLC will bolster its leading position in the vaccine market and strengthen its development pipeline. The deal, expected to close by the end of September, would add Acambis' key smallpox vaccine ACAM2000 to the existing portfolio of Sanofi Pasteur, the vaccines business of Sanofi-Aventis. Sanofi Pasteur has a drug-development center in Malvern and facilities in Swiftwater, Pa., in the Poconos. In April, Acambis won a $425 million, 10-year contract to provide the U.S. government with its ACAM2000 vaccine, which is the mainstay of the U.S. stockpile against smallpox.
June 16, 2008 |
Sanofi Pasteur, of Swiftwater in Northeastern Pennsylvania, said today it would donate 60 million doses of influenza vaccine to the World Health Organization. The vaccine, to be supplied over three years, will help build a stockpile that can be used in poor regions of the world in the event of an outbreak of pandemic influenza. Sanofi-Pasteur is the vaccines division of Sanofi-Aventis Group, the Paris pharmaceutical company. It has U.S. research and development headquarters in Malvern.
August 26, 2010
Sanofi Pasteur said the U.S. Food and Drug Administration had accepted its application to extend the age group that can receive a vaccine that can prevent meningococcal disease. Sanofi Pasteur, the vaccines division of French drugmaker Sanofi-Aventis with U.S. headquarters in Swiftwater, Monroe County, said the FDA was reviewing its supplemental biologics license application for Menactra to be used in infants and toddlers. All of the Menactra vaccine is made in Swiftwater, said Sanofi spokeswoman Susan Watkins.
November 11, 2005 |
Few small biotechnology companies would call ending a licensing agreement with a major pharmaceutical company a positive development. But Aphton Corp. did just that yesterday, announcing its agreement with Sanofi Pasteur was terminated to allow the smaller company to pursue another partner. Aphton and Sanofi Pasteur dissolved a licensing agreement, signed in 1997, that called for Sanofi Pasteur to copromote Aphton's cancer compound, Insegia. The move allows Aphton to seek a new partner to financially support additional clinical studies of its drug for gastric cancer.
July 4, 2006 |
Sanofi Pasteur Inc., the vaccine-maker in northeastern Pennsylvania, has found and destroyed a small amount of contaminated vaccine material at its plant, the company and regulators said yesterday. The contaminated bulk vaccine concentrate was never refined into the actual vaccine, Fluzone, or released to the public, the officials said. The company said the "unusual" contamination was discovered during a routine inspection and was reported in March to the Food and Drug Administration.
October 24, 2006 |
Drug-safety officials and the vaccine-maker Sanofi Pasteur are studying reports of a rare paralysis condition among at least 15 young people among millions vaccinated with Menactra, its meningitis vaccine. The cases of Guillain-Barre Syndrome, occurring six weeks after vaccinations, amounted to about 1.25 people out of one million vaccinated nationwide, according to officials at the U.S. Centers for Disease Control and Prevention. An estimated 6.6 million doses of the vaccine, manufactured in Swiftwater, Pa., about 100 miles north of Philadelphia, have been administered since it was introduced in March 2005, the company said.
March 13, 2014 |
Until now, hospitals have largely dealt with Clostridium difficile , a bacterial infection that bedevils vulnerable patients in health-care settings, by attempting to prevent it with intensive disinfection or treating it with antibiotics. Temple University Hospital is trying something new: a vaccine. Temple is among 200 sites in 17 countries that are testing a new vaccine produced by Sanofi Pasteur in Swiftwater, Pa. The Phase III clinical trial, known as Cdiffense, aims to recruit up to 15,000 adults.
September 16, 2005 |
The federal government said yesterday that it had awarded Sanofi Pasteur Inc. a $100 million contract to produce an avian flu vaccine. It also awarded GlaxoSmithKline P.L.C. a $2.8 million contract to supply its antiviral drug Relenza, which can be used to treat influenza. The Department of Health and Human Services said the contracts were part of the government's plan to buy enough vaccine for 20 million people and antivirals to treat 20 million more in the event of an avian flu pandemic.
April 28, 2009 |
There is no vaccine against the deadly new strain of swine flu, but the federal government is pondering whether to make one. That's a tricky decision, but if the Centers for Disease Control and Prevention gives the go-ahead, it likely will turn to pharmaceutical companies with operations in this region. In the Poconos, the French vaccine-maker Sanofi Pasteur already has the capacity to churn out 50 million doses of its seasonal influenza vaccine, Fluzone, which protects against a different strain of the flu. Spokeswoman Donna Cary said the company was ready to help the CDC should the agency decide to create and manufacture a vaccine against the swine flu. The company also is close to bringing a new vaccine facility into full production at the Swiftwater, Pa., location that will double its capacity, Cary said.